CTAS vs PCVX · P/E 51, rev $10.34B vs $6.84B cap
Cintas Corporation (CTAS) versus Vaxcyte Inc (PCVX) — a side-by-side from cached financials, not a winner call.
Cintas Corporation (CTAS) is a specialty business services company listed on US.
Vaxcyte Inc (PCVX) is a biotechnology company listed on US.
Latest reported CTAS revenue for 2025-05-31 was $10.34B. Net income was $1.81B. Revenue was up 7.7% from 2024-05-31 to 2025-05-31. CTAS currently screens at market cap $89.01B and trailing P/E 51.3.
PCVX does not have a complete income-statement cache yet.
CTAS currently screens at market cap $89.01B and trailing P/E 51.3. PCVX currently screens at market cap $6.84B.
Not investment advice. Open the CTAS and PCVX stock pages for the full models.
Not investment advice.